Ascendis Pharma A/S (ASND) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Ascendis Pharma A/S (NASDAQ: ASND) in the last few weeks:

• 8/18/2026 – Ascendis Pharma A/S is now covered by BMO Capital Markets. They set an “outperform” rating and a $319.00 price target on the stock.
• 8/18/2026 – Ascendis Pharma A/S is now covered by BMO Capital Markets. They set an “outperform” rating and a $319.00 price target on the stock.
• 8/15/2026 – Ascendis Pharma A/S was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/14/2026 – Ascendis Pharma A/S had its price target raised by Royal Bank Of Canada from $280.00 to $290.00. They now have an “outperform” rating on the stock.
• 8/14/2026 – Ascendis Pharma A/S had its price target raised by TD Cowen from $325.00 to $341.00. They now have a “buy” rating on the stock.
• 8/14/2026 – Ascendis Pharma A/S had its price target lowered by Barclays PLC from $345.00 to $329.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – Ascendis Pharma A/S had its “buy” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $333.00 price target on the stock.
• 7/23/2026 – Ascendis Pharma A/S had its price target raised by Morgan Stanley from $256.00 to $275.00. They now have an “overweight” rating on the stock.
• 7/18/2026 – Ascendis Pharma A/S was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/15/2026 – Ascendis Pharma A/S was upgraded by Weiss Ratings from “sell (d)” to “hold (c)”.
• 7/7/2026 – Ascendis Pharma A/S had its price target raised by Royal Bank Of Canada from $275.00 to $280.00. They now have an “outperform” rating on the stock.
• 7/4/2026 – Ascendis Pharma A/S was upgraded by Wall Street Zen from “hold” to “buy”.

Insider Transactions at Ascendis Pharma A/S

In related news, Director Jean Jacques Bienaime bought 2,000 shares of the firm’s stock in a transaction on Friday, August 14th. The shares were bought at an average price of $246.33 per share, with a total value of $492,660.00. Following the completion of the transaction, the director directly owned 2,900 shares of the company’s stock, valued at $714,357. This represents a 222.22% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 40.00% of the company’s stock.

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.